Gene · 51185
Papers2,935
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
821 to 840 of 2,935
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Targeted protein posttranslational modifications by chemically induced proximity for cancer therapy. | J Biol Chem | 2023 | 36870680 | PubTator, text mining | PubMed |
| USP35 promotes cell proliferation and chemotherapeutic resistance through stabilizing FUCA1 in colorectal cancer. | Oncogenesis | 2023 | 36864055 | PubTator, text mining | PubMed |
| Discovery and characterization of a selective IKZF2 glue degrader for cancer immunotherapy. | Cell Chem Biol | 2023 | 36863346 | PubTator, text mining | PubMed |
| Targeting p53 pathways: mechanisms, structures, and advances in therapy. | Signal Transduct Target Ther | 2023 | 36859359 | PubTator, text mining | PubMed |
| Recent Advances in PROTAC-Based Antiviral Strategies. | Vaccines (Basel) | 2023 | 36851148 | PubTator, text mining | PubMed |
| Non-syndromic Intellectual Disability: An Experimental In-Depth Exploration of Inheritance Pattern, Phenotypic Presentation, and Genomic Composition. | Cureus | 2023 | 36843831 | PubTator, text mining | PubMed |
| Structural-based design of HD-TAC7 PROteolysis TArgeting chimeras (PROTACs) candidate transformations to abrogate SARS-CoV-2 infection. | J Biomol Struct Dyn | 2023 | 36841549 | PubTator, text mining | PubMed |
| Cancer-Specific Delivery of Proteolysis-Targeting Chimeras (PROTACs) and Their Application to Cancer Immunotherapy. | Pharmaceutics | 2023 | 36839734 | PubTator, text mining | PubMed |
| Gene Regulatory Interactions at Lamina-Associated Domains. | Genes (Basel) | 2023 | 36833261 | PubTator, text mining | PubMed |
| The Role of CREBBP/EP300 and Its Therapeutic Implications in Hematological Malignancies. | Cancers (Basel) | 2023 | 36831561 | PubTator, text mining | PubMed |
| Lenalidomide-associated B-cell ALL: clinical and pathologic correlates and sensitivity to lenalidomide withdrawal. | Blood Adv | 2023 | 36827680 | PubTator, text mining | PubMed |
| Relapsed/Refractory Multiple Myeloma: A Review of Available Therapies and Clinical Scenarios Encountered in Myeloma Relapse. | Curr Oncol | 2023 | 36826140 | PubTator, text mining | PubMed |
| E3 Ligases Meet Their Match: Fragment-Based Approaches to Discover New E3 Ligands and to Unravel E3 Biology. | J Med Chem | 2023 | 36821822 | PubTator, text mining | PubMed |
| Molecular classification and therapeutics in diffuse large B-cell lymphoma. | Front Mol Biosci | 2023 | 36818048 | PubTator, text mining | PubMed |
| Predictive Modeling of PROTAC Cell Permeability with Machine Learning. | ACS Omega | 2023 | 36816707 | PubTator, text mining | PubMed |
| Genetic manipulation and targeted protein degradation in mammalian systems: practical considerations, tips and tricks for discovery research. | FEBS Open Bio | 2023 | 36815235 | PubTator, text mining | PubMed |
| Epigenetic regulation in hematopoiesis and its implications in the targeted therapy of hematologic malignancies. | Signal Transduct Target Ther | 2023 | 36797244 | PubTator, text mining | PubMed |
| BRD9 Degradation Disrupts Ribosome Biogenesis in Multiple Myeloma. | Clin Cancer Res | 2023 | 36780189 | PubTator, text mining | PubMed |
| A phase II multi-arm study of magrolimab combinations in patients with relapsed/refractory multiple myeloma. | Future Oncol | 2023 | 36779512 | PubTator, text mining | PubMed |
| Sec61 blockade therapy overrides resistance to proteasome inhibitors and immunomodulatory drugs in multiple myeloma. | Front Oncol | 2023 | 36776330 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/51185/papers?page=42